SecBot SecBot
6-K ·Filed Nov 12, 2026

MDWD

MediWound Ltd.
BEARISH
Impact 6/10
Horizonmonths Processed4d 20h ago SEC0001178913-26-005154
6-K: Earnings release
Actionable Insight ▼ Bearish

The revenue miss and uncertain government funding outlook are the primary negatives, partially offset by the recent capital raise extending runway. Watch for updates on U.S. government funding decisions for the planned manufacturing facility and enrollment completion of the EscharEx VALUE trial by Q1 2027.

DirectionBearish
Confidencehigh
Horizonmonths

EscharEx

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
Next catalyst
None dated

What to watchThe next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.

Price Chart

Loading chart...

Executive Summary

MediWound reported Q3 2026 revenue of $3.6M, down 33% YoY from $5.4M, and a net loss of $0.46 per share vs $0.24 a year ago. Revenue missed the $6.7M consensus by 46%, and the company disclosed that a substantial portion of 2026 revenue depends on uncertain U.S. government funding for a planned manufacturing facility. The balance sheet was strengthened by a $17.25M public offering closed after quarter-end, providing cash runway through the EscharEx Phase III VALUE data readout expected in early 2027.

Key Financial Metrics

EPS
−$0.46
est −$0.73 · +37.0%
Revenue
$3.6M
est $6.7M · -46.7% · -34.2% YoY
Rating
in line
Gross Margin
28.5%

Key Facts

  • Q3 2026 revenue $3.6M, down 33% YoY from $5.4M, missing $6.7M consensus
  • Net loss $6.0M ($0.46 per share) vs $2.7M ($0.24 per share) a year ago
  • Cash burn $28.3M in first nine months of 2026; cash fell to $28.4M from $53.6M at year-end 2025
  • Closed $17.25M underwritten public offering in November 2026 (9.2% dilution vs Sept 30 shares)
  • 2026 revenue outlook uncertain: substantial portion depends on U.S. government funding discussions
  • EscharEx Phase III VALUE trial enrollment and interim assessment on track for Q1 2027
  • NexoBrid had strongest quarterly revenue since launch per Vericel; BARDA procurement began in Q3
  • U.S. DoW awarded $3.3M additional non-dilutive funding for NexoBrid room-temperature-stable formulation

Financial Impact

Revenue miss of $3.1M vs consensus (46% shortfall); net loss widened by $3.3M YoY; cash burn of $28.3M in 9 months; $17.25M gross proceeds from offering provide ~6 months of runway at current burn rate

revenuenet losscash burndilution

Risk Factors

  • Substantial portion of 2026 revenue dependent on uncertain U.S. government funding for manufacturing facility
  • Cash burn rate of ~$28M over 9 months implies limited runway despite recent $17.25M offering
  • Revenue decline driven by lower development services revenue from U.S. government; no visibility on recovery
  • EscharEx Phase III trial still enrolling; no efficacy data until at least Q1 2027 interim analysis

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-005154
Document: zk2636401.htm0001178913-26-005154
Document: 0001178913-26-005154-index-headers.html0001178913-26-005154
Document: 0001178913-26-005154-index.html0001178913-26-005154
Document: 0001178913-26-005154.txt0001178913-26-005154
Earnings Context (Synthetic; results releases only)0001178913-26-005154

Track record

13 reports on MDWD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +20.80% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
  2. Nov 12, 20264d ago 6-K Bearish 6/10 Viewing No price data
  3. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $12.97 Now $13.55 −4.47% settles Nov 19
  4. Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
  6. Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
  7. Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
  8. Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
  9. May 27, 202624w ago Press Release Bearish 5/10 Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
  10. May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026